Published in J Virol on November 01, 2006
Low pH-induced conformational change in herpes simplex virus glycoprotein B. J Virol (2010) 1.16
Cholesterol dependence of varicella-zoster virion entry into target cells. J Virol (2007) 1.10
A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways. PLoS One (2010) 1.10
Low-pH-dependent changes in the conformation and oligomeric state of the prefusion form of herpes simplex virus glycoprotein B are separable from fusion activity. J Virol (2011) 0.95
Intracytoplasmic trapping of influenza virus by a lipophilic derivative of aglycoristocetin. J Virol (2012) 0.88
Role of the UL45 protein in herpes simplex virus entry via low pH-dependent endocytosis and its relationship to the conformation and function of glycoprotein B. Virus Res (2010) 0.84
Varicella-zoster viruses associated with post-herpetic neuralgia induce sodium current density increases in the ND7-23 Nav-1.8 neuroblastoma cell line. PLoS One (2013) 0.81
Neuronal changes induced by Varicella Zoster Virus in a rat model of postherpetic neuralgia. Virology (2015) 0.78
Polyethylene glycol-mediated fusion of herpes simplex type 1 virions with the plasma membrane of cells that support endocytic entry. Virol J (2015) 0.77
Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell (1996) 9.03
Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science (1998) 7.89
A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell (1999) 6.82
Herpesvirus entry: an update. J Virol (2003) 5.19
Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol (1992) 4.48
Three classes of cell surface receptors for alphaherpesvirus entry. Virology (2000) 4.41
Glycoproteins gB, gD, and gHgL of herpes simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a Cos cell transfection system. J Virol (1998) 3.98
Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface. Proc Natl Acad Sci U S A (1987) 3.96
Cell fusion induced by herpes simplex virus glycoproteins gB, gD, and gH-gL requires a gD receptor but not necessarily heparan sulfate. Virology (2001) 3.82
Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest (2001) 3.64
Neutralizing antibodies specific for glycoprotein H of herpes simplex virus permit viral attachment to cells but prevent penetration. J Virol (1989) 3.20
Roles for endocytosis and low pH in herpes simplex virus entry into HeLa and Chinese hamster ovary cells. J Virol (2003) 3.14
Poxvirus tropism. Nat Rev Microbiol (2005) 3.07
Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol (1995) 2.87
Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during latency. Proc Natl Acad Sci U S A (1998) 2.65
The etiologic agents of varicella and herpes zoster; isolation, propagation, and cultural characteristics in vitro. J Exp Med (1958) 2.62
PENETRATION OF HERPES SIMPLEX VIRUS INTO HUMAN EPIDERMOID CELLS. Proc Soc Exp Biol Med (1965) 2.42
Mode of inhibition of herpes simplex virus DNA polymerase by phosphonoacetate. Biochemistry (1975) 2.37
Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J Virol (1995) 2.24
Herpes simplex virus type 1 enters human epidermal keratinocytes, but not neurons, via a pH-dependent endocytic pathway. J Virol (2005) 2.19
Cellular and viral requirements for rapid endocytic entry of herpes simplex virus. J Virol (2004) 2.17
Glycoprotein D receptor-dependent, low-pH-independent endocytic entry of herpes simplex virus type 1. J Virol (2005) 2.07
Sequential isolation of proteoglycan synthesis mutants by using herpes simplex virus as a selective agent: evidence for a proteoglycan-independent virus entry pathway. J Virol (1995) 2.02
Plasma membrane requirements for cell fusion induced by herpes simplex virus type 1 glycoproteins gB, gD, gH and gL. J Gen Virol (2001) 1.78
Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73
Cell surface expression and fusion by the varicella-zoster virus gH:gL glycoprotein complex: analysis by laser scanning confocal microscopy. Virology (1995) 1.72
Varicella-zoster virus open reading frame 10 protein, the herpes simplex virus VP16 homolog, transactivates herpesvirus immediate-early gene promoters. J Virol (1993) 1.71
Genetic control of retrovirus susceptibility in mammalian cells. Annu Rev Genet (2004) 1.69
Varicella-zoster virus glycoprotein oligosaccharides are phosphorylated during posttranslational maturation. J Virol (1989) 1.62
Infection of cells by varicella zoster virus: inhibition of viral entry by mannose 6-phosphate and heparin. Proc Natl Acad Sci U S A (1995) 1.60
Membrane fusion mediated by herpesvirus glycoproteins: the paradigm of varicella-zoster virus. Rev Med Virol (2003) 1.58
Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons. J Virol (2006) 1.54
Multiple regulatory effects of varicella-zoster virus (VZV) gL on trafficking patterns and fusogenic properties of VZV gH. J Virol (1996) 1.49
Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol (2005) 1.48
Varicella-Zoster virus gene expression in latently infected rat dorsal root ganglia. Virology (2001) 1.45
Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell (2004) 1.45
Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. Virology (1993) 1.36
Virion association of IE62, the varicella-zoster virus (VZV) major transcriptional regulatory protein, requires expression of the VZV open reading frame 66 protein kinase. J Virol (2001) 1.27
An in vivo model of varicella-zoster virus latent infection of dorsal root ganglia. J Neurosci Res (1990) 1.25
Characteristics of herpes zoster and varicella viruses propagated in vitro. J Immunol (1965) 1.24
T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection. J Virol (2005) 1.19
Varicella-zoster virus open reading frame 2 encodes a membrane phosphoprotein that is dispensable for viral replication and for establishment of latency. J Virol (2002) 1.17
Cell surface proteoglycans are not essential for infection by pseudorabies virus. J Virol (1995) 1.17
Regulated nuclear localization of the varicella-zoster virus major regulatory protein, IE62. J Infect Dis (1998) 1.17
Translation of varicella-zoster virus genes during human ganglionic latency. Virus Genes (2004) 1.15
Phosphorylation of the varicella-zoster virus (VZV) major transcriptional regulatory protein IE62 by the VZV open reading frame 66 protein kinase. J Virol (2006) 1.15
Varicella-zoster virus latency in the adult rat is a useful model for human latent infection. Neurology (1995) 1.13
Analysis of three late varicella-zoster virus proteins, a 125,000-molecular-weight protein and gp1 and gp3. J Virol (1984) 1.12
Evidence for an interaction of herpes simplex virus with chondroitin sulfate proteoglycans during infection. Virology (1995) 1.08
The bovine mannose 6-phosphate/insulin-like growth factor II receptor. The role of arginine residues in mannose 6-phosphate binding. J Biol Chem (1993) 1.04
The effect of phosphonoacetic acid on the in vitro replication of varicella-zoster virus. Intervirology (1977) 1.04
Varicella-zoster virus infection of adult rat sensory neurons in vitro. J Virol (1989) 1.02
Regulation of varicella-zoster virus-induced cell-to-cell fusion by the endocytosis-competent glycoproteins gH and gE. J Virol (2004) 0.98
Viral gene expression in rat trigeminal ganglia following neonatal infection with varicella-zoster virus. J Med Virol (1999) 0.96
Use of a rodent model to show that varicella-zoster virus ORF61 is dispensable for establishment of latency. J Med Virol (2003) 0.95
Infection of Chinese hamster ovary cells by pseudorabies virus. J Virol (1999) 0.95
Equine herpesvirus 1 utilizes a novel herpesvirus entry receptor. J Virol (2005) 0.95
The varicella zoster virus glycoprotein B (gB) plays a role in virus binding to cell surface heparan sulfate proteoglycans. Virus Res (1998) 0.94
Evidence of latent varicella-zoster virus in rat dorsal root ganglia. J Infect Dis (1998) 0.88
A mouse model for varicella-zoster virus latency. Microb Pathog (1993) 0.85
Acute and persistent varicella-zoster virus infection of human and murine neuroblastoma cell lines. J Neurosci Res (1990) 0.80
Functions of purified gB, gE:gI, and gH:gL, and their sialyl residues in varicella-zoster virus infection. Arch Virol (1997) 0.79
Chronic uveitis in guinea pigs infected with varicella-zoster virus expressing Escherichia coli beta-galactosidase. J Infect Dis (1998) 0.78
Recommendations for the management of herpes zoster. Clin Infect Dis (2007) 4.33
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med (2015) 4.23
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis (2012) 3.94
Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med (2012) 2.77
Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med (2010) 2.73
Validation of a 3-factor scoring model for the Pittsburgh sleep quality index in older adults. Sleep (2006) 2.62
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis (2012) 2.55
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin (2009) 2.51
Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain (2004) 2.15
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis (2009) 2.13
The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother (2012) 2.11
The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain (2007) 2.08
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine (2007) 2.01
Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2012) 1.98
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol (2010) 1.96
Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev (2003) 1.95
The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ (2010) 1.88
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2014) 1.81
Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc (2010) 1.76
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin (2011) 1.73
DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis (2007) 1.71
Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis (2008) 1.70
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2013) 1.69
The prevention and management of herpes zoster. Med J Aust (2008) 1.60
Intravitreal injection of the attenuated pseudorabies virus PRV Bartha results in infection of the hamster suprachiasmatic nucleus only by retrograde transsynaptic transport via autonomic circuits. J Neurosci (2002) 1.55
The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses (2010) 1.47
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin (2011) 1.46
Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. Arch Pediatr Adolesc Med (2004) 1.44
A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol (2009) 1.42
Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry (2008) 1.38
Management of warfarin in children with heart disease. Pediatr Cardiol (2011) 1.38
Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J (2006) 1.32
Critical role of extracellular heat shock cognate protein 70 in the myocardial inflammatory response and cardiac dysfunction after global ischemia-reperfusion. Am J Physiol Heart Circ Physiol (2008) 1.24
A prospective study of the herpes zoster severity of illness. Clin J Pain (2010) 1.22
Entry of herpes simplex virus type 1 into primary sensory neurons in vitro is mediated by Nectin-1/HveC. J Virol (2003) 1.20
Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. J Virol (2005) 1.19
VZV T cell-mediated immunity. Curr Top Microbiol Immunol (2010) 1.17
Endomorphin-1 modulates intrinsic inhibition in the dorsal vagal complex. J Neurophysiol (2007) 1.15
Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis (2010) 1.14
The attenuated pseudorabies virus strain Bartha fails to package the tegument proteins Us3 and VP22. J Virol (2003) 1.11
The pseudorabies virus serine/threonine kinase Us3 contains mitochondrial, nuclear and membrane localization signals. Virus Genes (2004) 1.10
Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis (2013) 1.09
Nectin-1/HveC Mediates herpes simplex virus type 1 entry into primary human sensory neurons and fibroblasts. J Neurovirol (2005) 1.08
A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J (2009) 1.06
Human sensory neurons derived from induced pluripotent stem cells support varicella-zoster virus infection. PLoS One (2012) 1.05
Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine (2012) 1.05
Varicella-zoster virus DNA in cells isolated from human trigeminal ganglia. J Virol (2003) 1.05
The pseudorabies virus Us2 protein, a virion tegument component, is prenylated in infected cells. J Virol (2003) 1.04
Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine (2010) 1.04
Varicella vaccine in the United States: a decade of prevention and the way forward. J Infect Dis (2008) 1.02
Impairments in health functioning and sleep quality in older adults with a history of depression. J Am Geriatr Soc (2006) 1.01
Analysis of filamentous process induction and nuclear localization properties of the HSV-2 serine/threonine kinase Us3. Virology (2009) 1.00
Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics (2007) 1.00
Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine. Vaccine (2009) 0.98
Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2009) 0.97
IL-27 enhances LPS-induced proinflammatory cytokine production via upregulation of TLR4 expression and signaling in human monocytes. J Immunol (2011) 0.97
Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob Agents Chemother (2002) 0.96
Major depressive disorder and immunity to varicella-zoster virus in the elderly. Brain Behav Immun (2011) 0.96
Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine (2007) 0.95
Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis (2005) 0.95
Persistent sleep disturbance: a risk factor for recurrent depression in community-dwelling older adults. Sleep (2013) 0.94
Hyperphosphorylation of histone deacetylase 2 by alphaherpesvirus US3 kinases. J Virol (2010) 0.93
Post-transcriptional regulation of TNF-induced expression of ICAM-1 and IL-8 in human lung microvascular endothelial cells: an obligatory role for the p38 MAPK-MK2 pathway dissociated with HSP27. Biochim Biophys Acta (2008) 0.92
Localization of ERK/MAP kinase is regulated by the alphaherpesvirus tegument protein Us2. J Virol (2006) 0.92
Central sympathetic innervations to visceral and subcutaneous white adipose tissue. Am J Physiol Regul Integr Comp Physiol (2014) 0.91
The herpes simplex virus 2 UL21 protein is essential for virus propagation. J Virol (2013) 0.91
Innervation of skeletal muscle by leptin receptor-containing neurons. Brain Res (2010) 0.90
Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clin Infect Dis (2013) 0.89
Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. Infect Dis Obstet Gynecol (2010) 0.89
Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy. Vaccine (2013) 0.89
Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis (2007) 0.89
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine (2011) 0.88
Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother (2013) 0.87
Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis (2013) 0.87
Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2004) 0.87
Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis (2012) 0.87
Fractionation of neurons and satellite cells from human sensory ganglia in order to study herpesvirus latency. J Virol Methods (2002) 0.86
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study. Hum Vaccin Immunother (2014) 0.86
Herpes simplex virus 2 infection impacts stress granule accumulation. J Virol (2012) 0.86
Resistance to antiretrovirals in HIV-infected pregnant women. J Clin Virol (2009) 0.85
The alphaherpesvirus US3/ORF66 protein kinases direct phosphorylation of the nuclear matrix protein matrin 3. J Virol (2010) 0.83
Safety and tolerability of antiretrovirals during pregnancy. Infect Dis Obstet Gynecol (2011) 0.82
IL-27 increases BST-2 expression in human monocytes and T cells independently of type I IFN. Sci Rep (2012) 0.82
Workshop on immunizations in older adults: identifying future research agendas. J Am Geriatr Soc (2010) 0.82
Immune correlates of herpes zoster in HIV-infected children and youth. J Virol (2011) 0.82
Dysregulation of autophagy in murine fibroblasts resistant to HSV-1 infection. PLoS One (2012) 0.81
Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin (2010) 0.81
The alphaherpesvirus serine/threonine kinase us3 disrupts promyelocytic leukemia protein nuclear bodies. J Virol (2011) 0.81
Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Curr Opin Virol (2011) 0.80
T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines. AIDS Res Hum Retroviruses (2010) 0.80
Immune response to a refrigerator-stable zoster vaccine. Clin Vaccine Immunol (2009) 0.80
Factors that affect in vitro measurement of the susceptibility of herpes simplex virus to nucleoside analogues. J Clin Virol (2006) 0.79
Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol (2010) 0.79
Papillary lesions of the breast diagnosed by core needle biopsy: 71 cases with surgical follow-up. Am J Surg (2008) 0.79
GB virus C infection in children with perinatal human immunodeficiency virus infection. Pediatr Infect Dis J (2005) 0.79